Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-02-13 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Shanghai Medicilon Biopharmaceutical Co., Ltd. regarding the approval from the China Securities Regulatory Commission (CSRC) for the company's application to issue shares to specific investors. It references the regulatory approval document and outlines the conditions and validity period of the approval. The content focuses on the company's capital raising activity through a specific share issuance and the related regulatory consent. There are no financial statements or detailed financial performance data included, nor is it a report or presentation. The document is clearly an update on a capital/financing activity, specifically a share issuance approval. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not merely a report publication announcement or a regulatory filing fallback.
2023-02-13 Chinese
美迪西：第三届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed by the Supervisory Board (监事会) of Shanghai Medicilon Inc. It details the meeting date, attendance, and the approval of an extension of the validity period for a shareholder meeting resolution related to a specific issuance of A shares. The document does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is an official announcement of a board/management decision regarding company governance and corporate actions. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on a board resolution, not a full report or regulatory filing. Confidence is high due to clear keywords like '监事会会议决议公告' (Supervisory Board Meeting Resolution Announcement) and the nature of the content.
2023-02-10 Chinese
美迪西：第三届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shanghai Medicilon Inc. It details the meeting date, attendance, and specific resolutions related to extending the validity period of a shareholder meeting resolution and authorization concerning a 2022 private placement of A shares. It also mentions the proposal to convene the 2023 first extraordinary general meeting. The document does not contain financial statements or detailed financial data but is an official announcement of board decisions. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is under 5,000 characters and is a direct announcement, not a report publication notice. Therefore, the classification is MANG with high confidence.
2023-02-10 Chinese
美迪西：关于召开2023年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2023 first extraordinary general meeting of shareholders (临时股东大会) for Shanghai Medicilon Biopharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and includes an authorization proxy form. There is no financial data, earnings, or management discussion. It is not a report or results announcement but a formal meeting notice and related procedural information. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2023-02-10 Chinese
美迪西：关于第三届董事会第十三次会议相关事项的独立意见
Regulatory Filings
2023-02-10 Chinese
美迪西：关于延长公司2022年度向特定对象发行A股股票股东大会决议有效期及相关授权有效期的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shanghai Medicilon Inc. regarding the extension of the validity period of a shareholders' meeting resolution and related authorizations concerning a specific issuance of A shares in 2022. It details board and supervisory meetings, shareholder meeting decisions, and independent director opinions on the extension. The document does not contain financial statements or detailed financial data but is an official announcement about corporate governance and shareholder meeting resolutions related to capital issuance. It is not a full report, earnings release, or financial supplement. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about corporate actions and meeting resolutions without substantive financial data or report content.
2023-02-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.